ImPact Biotech Reports 73% Complete Response Rate in Phase 3 ENLIGHTED Trial of Padeliporfin VTP for Low-Grade UTUC
核心洞察
ImPact Biotech (搜索) will present updated interim Phase 3 data from the ENLIGHTED study of Padeliporfin VTP therapy for low-grade upper tract urothelial carcinoma at SUO 2025 in December.
The interim analysis showed Padeliporfin VTP induced a complete response in 73% (27/37) of evaluable patients while maintaining a safe and well-tolerated profile.
The interim results captured data from 50% of target enrollment in the pivotal Phase 3 study as of November 5, 2024 data cutoff.
ImPact Biotech (搜索) announced it will present updated interim results from its pivotal Phase 3 ENLIGHTED study of Padeliporfin vascular targeted photodynamic (VTP) therapy for low-grade upper tract urothelial carcinoma (UTUC) at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025) taking place December 2-5, 2025, in Phoenix, Arizona.
The clinical-stage biotechnology company previously reported promising interim data showing Padeliporfin VTP induced a complete response (CR) in 73% (27/37) of evaluable patients while maintaining a safe and well-tolerated profile. The interim analysis captured results from 50% of target enrollment in ENLIGHTED as of the November 5, 2024 data cutoff.
Conference Presentation Details
The updated data will be presented as a poster titled "ENLIGHTED Phase 3 study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC)" by Vitaly Margulis, M.D., Professor of Urologic Oncology at University of Texas Southwestern Medical Center. The presentation is scheduled for December 4, 2025, at 4:30 PM MST as part of the SUO Top Abstract Tour session.
The company recently delivered an encore presentation of the Phase 3 ENLIGHTED trial data at the 17th European Multidisciplinary Congress on Urological Cancers (EMUC 2025) on November 15, 2025, featuring the same interim analysis that was previously presented at ASCO 2025.
Padeliporfin VTP Technology Platform
Padeliporfin VTP represents a minimally invasive drug-device combination therapy designed for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment.
Beyond the current Phase 3 study in low-grade UTUC, Padeliporfin VTP is being evaluated in earlier stage studies for high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC).
Company Background
ImPact Biotech (搜索) operates as an advanced clinical-stage oncology company focused on developing and commercializing Padeliporfin VTP therapy across multiple solid tumor indications. The company maintains longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center, with operations spanning the EU, Israel, and the United States.